novel

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing…

4 months ago

ESOT Congress 2025: Scientists create functional human islets in 3D printing breakthrough for type 1 diabetes treatment

LONDON, June 28, 2025 /PRNewswire/ -- A team of international scientists has made a major leap forward in diabetes research…

4 months ago

Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessas Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist

July 04, 2025 03:00 ET  | Source: Nxera Pharma Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma…

4 months ago

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

June 20, 2025 19:30 ET  | Source: Structure Therapeutics Inc. SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics…

5 months ago

Inaugural Archer Amish Award Winner Announced at IGF London 2025

U.K Minister for Culture Lisa Nandy presents $25,000 award to Dr. Shalini Mullick for her novel The Way Home LONDON,…

5 months ago

Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update

June 19, 2025 01:00 ET  | Source: Addex Therapeutics Strong cash position of CHF2.8 million at end of Q1 2025GABAB…

5 months ago

Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025

June 18, 2025 01:00 ET  | Source: Addex Therapeutics Geneva, Switzerland, June 18, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a…

5 months ago

Positive Late-Breaking Data for Incytes First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy…

5 months ago

RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

June 13, 2025 09:00 ET  | Source: RAPT Therapeutics, Inc. SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) --…

5 months ago

Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer’s Disease

TAINAN, June 13, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial…

5 months ago